EssilorLuxottica (OTCMKTS:ESLOY) Upgraded at Kepler Capital Markets

Kepler Capital Markets upgraded shares of EssilorLuxottica (OTCMKTS:ESLOY) from a hold rating to a buy rating in a research report released on Thursday morning, MarketBeat Ratings reports.

ESLOY has been the topic of several other research reports. UBS Group upgraded shares of EssilorLuxottica from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 27th. Citigroup reissued a “buy” rating on shares of EssilorLuxottica in a research report on Thursday, December 11th. HSBC upgraded shares of EssilorLuxottica from a “hold” rating to a “buy” rating in a research report on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating on shares of EssilorLuxottica in a report on Tuesday, October 28th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of EssilorLuxottica in a report on Friday, December 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, EssilorLuxottica presently has an average rating of “Buy”.

EssilorLuxottica Stock Down 3.3%

ESLOY opened at $157.68 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.67 and a current ratio of 0.97. The stock’s 50 day simple moving average is $169.15 and its 200 day simple moving average is $161.94. EssilorLuxottica has a 1 year low of $125.26 and a 1 year high of $186.81.

EssilorLuxottica Company Profile

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.